Humana (NYSE:HUM) Releases FY 2026 Earnings Guidance

Humana (NYSE:HUM) issued an update on its FY 2026 earnings guidance on Wednesday morning. The company provided EPS guidance of 9.000-9.000 for the period, compared to the consensus EPS estimate of 12.030. The company issued revenue guidance of -.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on HUM shares. Morgan Stanley restated an “underperform” rating on shares of Humana in a report on Thursday, December 18th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Humana in a report on Thursday, January 22nd. Robert W. Baird reduced their target price on Humana from $280.00 to $264.00 and set a “neutral” rating on the stock in a report on Thursday, December 11th. Sanford C. Bernstein reaffirmed an “outperform” rating and issued a $344.00 price objective on shares of Humana in a research note on Tuesday, January 6th. Finally, Barclays reissued an “underperformer” rating on shares of Humana in a research note on Monday, January 5th. Eight equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and five have given a Sell rating to the company’s stock. According to MarketBeat.com, Humana presently has a consensus rating of “Hold” and a consensus target price of $293.21.

Humana Price Performance

NYSE HUM traded down $7.88 during trading hours on Wednesday, hitting $173.42. 4,359,968 shares of the company’s stock traded hands, compared to its average volume of 2,285,118. The company has a market capitalization of $20.86 billion, a PE ratio of 16.26, a PEG ratio of 1.57 and a beta of 0.44. The company has a debt-to-equity ratio of 0.68, a current ratio of 2.02 and a quick ratio of 2.02. Humana has a 52-week low of $169.61 and a 52-week high of $315.35. The firm’s 50-day moving average is $249.25 and its 200-day moving average is $262.36.

Humana (NYSE:HUM) last posted its earnings results on Wednesday, February 11th. The insurance provider reported ($3.96) earnings per share for the quarter, beating the consensus estimate of ($4.01) by $0.05. The company had revenue of $32.64 billion for the quarter, compared to analyst estimates of $32.08 billion. Humana had a net margin of 1.02% and a return on equity of 12.86%. Humana’s revenue was up 11.3% on a year-over-year basis. During the same period in the previous year, the business posted ($2.16) EPS. Humana has set its FY 2026 guidance at 9.000-9.000 EPS. Equities analysts forecast that Humana will post 16.47 EPS for the current fiscal year.

Humana News Summary

Here are the key news stories impacting Humana this week:

• Positive Sentiment: Q4 results slightly beat expectations: Humana reported adjusted EPS of ($3.96) vs. consensus ($4.01) and revenue of $32.64B (up ~11% YoY), which shows underlying top‑line growth and a small EPS upside. Humana (HUM) Reports Q4 Loss, Tops Revenue Estimates
• Neutral Sentiment: Company released the full earnings release and conference materials; the transcript and filings provide more detail on cost drivers and guidance assumptions for investors who want to dig into management commentary. Humana Reports Fourth Quarter 2025 Financial Results; Provides Full Year 2026 Financial Guidance
• Neutral Sentiment: Earnings call transcript is available for investors to review management’s commentary on medical cost trends and plan-quality actions. Humana (HUM) Q4 2025 Earnings Call Transcript
• Negative Sentiment: Weak FY‑2026 guidance: Humana guided EPS to 9.00 for FY‑2026 versus Street estimates near ~12.03, a material shortfall that directly pressures valuation and near‑term upside. Humana forecasts 2026 profit below estimates
• Negative Sentiment: Medicare Advantage headwinds and rising medical costs: Management cited higher medical costs and lower plan quality ratings exposure; analysts and press highlight a wider GAAP loss and margin pressure in the core MA business. Humana Loss Widens Amid Surging Medical Costs
• Negative Sentiment: Policy risk: Shares have been sensitive to federal moves on Medicare Advantage rates (government plan to keep 2027 MA rates nearly flat has driven outsized selling pressure). Humana Earnings Reveal Narrower-Than-Expected Loss. Why the Stock Is Falling.
• Negative Sentiment: Analyst caution — coverage notes and consensus revisions have turned more conservative after the guidance and MA headwinds, which limits near‑term upside. Are Wall Street Analysts Predicting Humana Stock Will Climb or Sink?

Hedge Funds Weigh In On Humana

Institutional investors have recently bought and sold shares of the company. CIBC Bancorp USA Inc. acquired a new stake in shares of Humana in the 3rd quarter worth approximately $4,321,000. Sunbelt Securities Inc. lifted its position in shares of Humana by 18.1% during the third quarter. Sunbelt Securities Inc. now owns 719 shares of the insurance provider’s stock worth $187,000 after purchasing an additional 110 shares in the last quarter. Coldstream Capital Management Inc. raised its holdings in Humana by 33.2% in the third quarter. Coldstream Capital Management Inc. now owns 2,427 shares of the insurance provider’s stock valued at $631,000 after acquiring an additional 605 shares in the last quarter. Danske Bank A S acquired a new stake in shares of Humana during the third quarter worth $15,040,000. Finally, Advisory Services Network LLC grew its position in shares of Humana by 356.5% during the third quarter. Advisory Services Network LLC now owns 5,583 shares of the insurance provider’s stock worth $1,453,000 after acquiring an additional 4,360 shares during the last quarter. 92.38% of the stock is owned by institutional investors and hedge funds.

About Humana

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.